Last updated on July 2019

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS


Brief description of study

To characterize the safety and tolerability of 1) MBG453 as a single agent or in combination with PDR001 or 2) PDR001 and/or MBG453 in combination with decitabine in AML and high risk MDS patients, and to identify recommended doses for future studies.

Clinical Study Identifier: NCT03066648

Find a site near you

Start Over

Novartis Investigative Site

Helsinki, Finland
6.93miles
  Connect »